Analysts Issue Forecasts for Nephros Inc.’s FY2017 Earnings (NEPH)
Nephros Inc. (OTCMKTS:NEPH) – Analysts at Seethru Equity issued their FY2017 earnings estimates for Nephros in a research report issued to clients and investors on Tuesday. Seethru Equity analyst A. Tandon expects that the company will post earnings per share of ($0.05) for the year.
Nephros (OTCMKTS:NEPH) last released its earnings results on Thursday, November 9th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.92 million for the quarter. Nephros had a negative return on equity of 358.70% and a negative net margin of 84.60%. COPYRIGHT VIOLATION WARNING: “Analysts Issue Forecasts for Nephros Inc.’s FY2017 Earnings (NEPH)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://theolympiareport.com/2017/11/19/analysts-issue-forecasts-for-nephros-inc-s-fy2017-earnings-neph.html.
Nephros (NEPH) opened at $0.47 on Friday. The company has a debt-to-equity ratio of 3.54, a current ratio of 1.13 and a quick ratio of 1.03. Nephros has a 1-year low of $0.18 and a 1-year high of $0.60.
Nephros Company Profile
Nephros, Inc (Nephros) is a commercial-stage medical device and commercial products company that develops and sells high performance liquid purification filters and hemodiafiltration (HDF) systems. The Company’s filters, ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate, and used in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas.
Receive News & Ratings for Nephros Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.